BACKGROUND: Endophenotypes in genetic psychiatry may increase our understanding of the molecular mechanisms underlying disease risk and its manifestations. We sought to investigate the link between neuropsychological impairments and brain structural abnormalities associated with the COMT Val(158)Met polymorphism in patients with schizophrenia to improve understanding of the pathophysiology of this disorder. METHODS: We performed a systematic review using studies identified in PubMed and MEDLINE (from the date of the first available article to July 2012). Our review examined evidence of an association between the COMT Val(158)Met polymorphism and both neuropsychological performance and brain structure in patients with psychosis, in their relatives and in healthy individuals (step 1). The review also explored whether the neuropsychological tasks and brain structures identified in step 1 met the criteria for an endophenotype (step 2). Then we evaluated evidence that the neuropsychological endophenotypes identified in step 2 are associated with the brain structure endophenotypes identified in that step (step 3). Finally, we propose a neurobiological interpretation for this evidence. RESULTS: A poorer performance on the n-back task and the Continuous Performance Test (CPT) and smaller temporal and frontal brain areas were associated with the COMT Val allele in patients with schizophrenia and their relatives and met most of the criteria for an endophenotype. It is possible that the COMT Val(158)Met polymorphism therefore contributes to the development of these neuropsychological and brain structural endophenotypes of schizophrenia, in which the prefrontal cortex may represent the neural substrate underlying both n-back and CPT performances. LIMITATIONS: The association between a single genetic variant and an endophenotype does not necessarily imply a causal relationship between them. CONCLUSION: This evidence and the proposed interpretation contribute to explain, at least in part, the biological substrate of 4 important endophenotypes that characterize schizophrenia.
BACKGROUND: Endophenotypes in genetic psychiatry may increase our understanding of the molecular mechanisms underlying disease risk and its manifestations. We sought to investigate the link between neuropsychological impairments and brain structural abnormalities associated with the COMTVal(158)Met polymorphism in patients with schizophrenia to improve understanding of the pathophysiology of this disorder. METHODS: We performed a systematic review using studies identified in PubMed and MEDLINE (from the date of the first available article to July 2012). Our review examined evidence of an association between the COMTVal(158)Met polymorphism and both neuropsychological performance and brain structure in patients with psychosis, in their relatives and in healthy individuals (step 1). The review also explored whether the neuropsychological tasks and brain structures identified in step 1 met the criteria for an endophenotype (step 2). Then we evaluated evidence that the neuropsychological endophenotypes identified in step 2 are associated with the brain structure endophenotypes identified in that step (step 3). Finally, we propose a neurobiological interpretation for this evidence. RESULTS: A poorer performance on the n-back task and the Continuous Performance Test (CPT) and smaller temporal and frontal brain areas were associated with the COMT Val allele in patients with schizophrenia and their relatives and met most of the criteria for an endophenotype. It is possible that the COMTVal(158)Met polymorphism therefore contributes to the development of these neuropsychological and brain structural endophenotypes of schizophrenia, in which the prefrontal cortex may represent the neural substrate underlying both n-back and CPT performances. LIMITATIONS: The association between a single genetic variant and an endophenotype does not necessarily imply a causal relationship between them. CONCLUSION: This evidence and the proposed interpretation contribute to explain, at least in part, the biological substrate of 4 important endophenotypes that characterize schizophrenia.
Authors: A Cerasa; A Cherubini; A Quattrone; M C Gioia; P Tarantino; G Annesi; F Assogna; C Caltagirone; G Spalletta Journal: Neuroscience Date: 2010-02-26 Impact factor: 3.590
Authors: A Dutt; C McDonald; E Dempster; D Prata; M Shaikh; I Williams; K Schulze; N Marshall; M Walshe; M Allin; D Collier; R Murray; E Bramon Journal: Psychol Med Date: 2009-07-02 Impact factor: 7.723
Authors: Axel Krug; Valentin Markov; Abigail Sheldrick; Sören Krach; Andreas Jansen; Klaus Zerres; Thomas Eggermann; Tony Stöcker; N Jon Shah; Tilo Kircher Journal: Eur Arch Psychiatry Clin Neurosci Date: 2009-04-21 Impact factor: 5.270
Authors: Susanne Karch; Gregor Leicht; Ina Giegling; Jürgen Lutz; Jörg Kunz; Moritz Buselmeier; Patric Hey; Alexander Spörl; Lorenz Jäger; Thomas Meindl; Oliver Pogarell; Hans-Jürgen Möller; Ulrich Hegerl; Dan Rujescu; Christoph Mulert Journal: J Psychiatr Res Date: 2009-05-07 Impact factor: 4.791
Authors: Nancy A Dennis; Anna C Need; Kevin S LaBar; Sheena Waters-Metenier; Elizabeth T Cirulli; James Kragel; David B Goldstein; Roberto Cabeza Journal: Cereb Cortex Date: 2009-07-29 Impact factor: 5.357
Authors: Benedicto Crespo-Facorro; Roberto Roiz-Santiáñez; Rocío Pérez-Iglesias; Diana Tordesillas-Gutiérrez; Ignacio Mata; José Manuel Rodríguez-Sánchez; Enrique Marco de Lucas; José Luis Vázquez-Barquero Journal: Schizophr Res Date: 2009-09-30 Impact factor: 4.939
Authors: Lachlan T Strike; Baptiste Couvy-Duchesne; Narelle K Hansell; Gabriel Cuellar-Partida; Sarah E Medland; Margaret J Wright Journal: Neuropsychol Rev Date: 2015-03-14 Impact factor: 7.444
Authors: Jibran Y Khokhar; Lucas L Dwiel; Angela M Henricks; Wilder T Doucette; Alan I Green Journal: Schizophr Res Date: 2017-04-14 Impact factor: 4.939
Authors: Sara Sannino; Alessandro Gozzi; Antonio Cerasa; Fabrizio Piras; Diego Scheggia; Francesca Managò; Mario Damiano; Alberto Galbusera; Lucy C Erickson; Davide De Pietri Tonelli; Angelo Bifone; Sotirios A Tsaftaris; Carlo Caltagirone; Daniel R Weinberger; Gianfranco Spalletta; Francesco Papaleo Journal: Cereb Cortex Date: 2014-03-21 Impact factor: 5.357
Authors: Jean-Pierre Lindenmayer; Anzalee Khan; Herbert Lachman; Susan R McGurk; Abraham Goldring; Amod Thanju; Saurabh Kaushik Journal: Schizophr Res Date: 2015-08-06 Impact factor: 4.939
Authors: Jackob Moskovitz; Consuelo Walss-Bass; Dianne A Cruz; Peter M Thompson; Marco Bortolato Journal: Int J Neuropsychopharmacol Date: 2014-04-15 Impact factor: 5.176
Authors: Yang I Li; Bryce van de Geijn; Anil Raj; David A Knowles; Allegra A Petti; David Golan; Yoav Gilad; Jonathan K Pritchard Journal: Science Date: 2016-04-28 Impact factor: 47.728